Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases [Yahoo! Finance]
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: Yahoo! Finance
on January 8 the selection of AMX0318 as a development candidate for post-bariatric hypoglycemia (PBH) and other rare diseases. AMX0318 is a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist and was identified through a research collaboration with Gubra A/S. Gubra A/S is involved in peptide-based drug discovery and preclinical contract research services. Camille L. Bedrosian, MD, Chief Medical Officer at Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), stated that AMX0318 has exhibited robust preclinical and chemical properties, including “a pharmacokinetic profile that may support long-acting administration.” Management further demonstrated strong conviction that inhibiting GLP-1 receptor activity marks a significant therapeutic approach, provided the statistically significant data that avexitide, its investigational, first-in-class GLP-1 receptor antagonist, has generated to date. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) expects the completion of recruitment in its pi
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/SBusiness Wire
- Amylyx Pharmaceuticals (NASDAQ:AMLX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=AMLX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
- Is Early AMX0114 Safety Data Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA TrialBusiness Wire
AMLX
Earnings
- 11/6/25 - Beat
AMLX
Sec Filings
- 1/16/26 - Form 144
- 1/16/26 - Form 144
- 1/15/26 - Form 144
- AMLX's page on the SEC website